Investigating how a specific RNA affects the survival of advanced breast cancer cells
Official title: Project 3: MANCR Mediates Epigenetic Mechanisms for Survival of Advanced Breast Cancer
Funded at University of Vermont & St Agric College · NIH-11074071 · Data updated 2026-11-12
This study is looking at a special molecule called MANCR that helps aggressive breast cancer cells survive, and by understanding how it works, the researchers hope to find new ways to treat patients with advanced breast cancer that doesn't respond to regular treatments.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $413,407 |
| NIH project number | 5P01CA240685-05 |
| Project ID | NIH-11074071 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced or aggressive breast cancer, particularly those with triple-negative or tamoxifen-resistant forms.
✕Less likely to help
Patients with early-stage breast cancer or those whose cancer is not aggressive may not benefit from this research.
What this research studies
This research focuses on a long non-coding RNA known as MANCR, which plays a crucial role in the survival of aggressive breast cancer cells. By examining how MANCR interacts with chromatin, the study aims to uncover the mechanisms that allow these cancer cells to thrive, particularly in cases that are resistant to standard treatments. The researchers will utilize advanced techniques to analyze chromatin organization and the effects of inhibiting MANCR, which could lead to new therapeutic strategies for patients with advanced breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target and kill aggressive breast cancer cells, improving patient outcomes.
How similar studies have gone: While the role of long non-coding RNAs in cancer is an emerging field, this specific approach targeting MANCR is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
University of Vermont & St Agric College
Burlington, United States Active
Researchers
- Principal investigator: Stein, Janet L — University of Vermont & St Agric College
- Study coordinator: Stein, Janet L
Related research
Other NIH-funded projects on the same topics.
-
Radiomic markers from 3D mammography to predict breast cancer risk across diverse women
A Mayo Clinic team is testing advanced computer-derived features from 3D mammograms to improve predicting who will develop breast cancer, including diverse groups of women.
-
Improving how the immune system fights advanced breast cancer by relieving tumor pressure
A breast cancer treatment study tests whether a common blood pressure drug (losartan) can help immune cells get into tumors and work better with immunotherapy.
-
Using a blood test that looks for tumor DNA to monitor early and locally advanced breast cancer
This project uses a sensitive blood test that looks for tiny bits of tumor DNA to track treatment response in people with early or locally advanced breast cancer.
-
Personalizing estrogen therapy for ER-positive breast cancer
This project finds how the hormone estrogen can kill certain ER-positive breast cancers and how to tell which patients will benefit.
-
Longer overnight fasting and exercise to reduce fatigue in women with hormone receptor–positive advanced breast cancer
This project will see if longer overnight fasting and regular exercise help women with hormone receptor–positive advanced breast cancer feel less fatigued and improve their quality of life.
-
FFNP-PET scans to predict hormone therapy response in advanced ER-positive breast cancer
This project uses a special PET scan called FFNP to find which people with ER-positive, HER2-negative advanced breast cancer are likely to benefit from hormone (endocrine) therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.